J&J files application in Europe for expanded use of Spravato

• Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies has filed a supplemental marketing application in Europe, called a Type II variation, seeking approval to use Spravato (esketamine) nasal spray as an acute short-term treatment, together with oral antidepressant therapy, for the rapid reduction of depressive symptoms in adults experiencing a moderate-to-severe depressive episode of major depressive disorder (MDD) who have suicidal ideation with intent.
• Spravato is currently approved (December 2019) in the EU for adults with treatment-resistant MDD, in combination with an SSRI or SNRI, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode.